



Certificate of Analysis for

Viobin LLC
226 Livingston St
Monticello, IL 61856
Phone: (217) 762-2561

Received: 3/7/2023 @ 13.3 °C
Report ID: 2303250
PO No.: SV-2756

Sample ID	Analyzed	Sample Description	Analysis	Result	Units	Method Code
2303250-001	3/9/2023	10mg Gummy G0223-01	Cannabichromene (CBC)	< 0.200	mg/gummy	CBD.1
	3/9/2023		Cannabicitran (CBT)	< 0.200	mg/gummy	CBD.1
	3/9/2023		Cannabidiol (CBD)	11.8	mg/gummy	CBD.1
	3/9/2023		Cannabidiolic Acid (CBDA)	< 0.100	mg/gummy	CBD.1
	3/9/2023		Cannabidivarin (CBDV)	< 0.100	mg/gummy	CBD.1
	3/9/2023		Cannabigerol (CBG)	< 0.100	mg/gummy	CBD.1
	3/9/2023		Cannabinol (CBN)	< 0.100	mg/gummy	CBD.1
	3/9/2023		Delta - 9 THC (THC)	< 0.100	mg/gummy	CBD.1
	3/9/2023		Delta 9 - Tetrahydrocannabinolic A	< 0.100	mg/gummy	CBD.1
	3/9/2023		Potential CBD	0.393	%	CBD.1
	3/9/2023		Potential THC	< 0.010	%	CBD.1
	3/9/2023		Tetrahydrocannabivarin (THCV)	< 0.100	mg/gummy	CBD.1

Reported By: _____

Ryan Connelly, Chemistry Laboratory Manager, 3/10/2023

Methodology:

CBD.1 : Cannabinoids via MBL-HPLC2




Certificate of Analysis for

Viobin LLC
 226 Livingston St
 Monticello, IL 61856
 Phone: (217) 762-2561

Received: 3/7/2023 @ 13.3 °C
 Report ID: 2303250
 PO No.: SV-2756

Sample ID	Analyzed	Sample Description	Analysis	Result	Units	Method Code
2303250-002	3/9/2023	10mg Gummy G0223-02	Cannabichromene (CBC)	< 0.200	mg/gummy	CBD.1
	3/9/2023		Cannabicitran (CBT)	< 0.200	mg/gummy	CBD.1
	3/9/2023		Cannabidiol (CBD)	11.3	mg/gummy	CBD.1
	3/9/2023		Cannabidiolic Acid (CBDA)	< 0.100	mg/gummy	CBD.1
	3/9/2023		Cannabidivarin (CBDV)	< 0.100	mg/gummy	CBD.1
	3/9/2023		Cannabigerol (CBG)	< 0.100	mg/gummy	CBD.1
	3/9/2023		Cannabinol (CBN)	< 0.100	mg/gummy	CBD.1
	3/9/2023		Delta - 9 THC (THC)	< 0.100	mg/gummy	CBD.1
	3/9/2023		Delta 9 - Tetrahydrocannabinolic A	< 0.100	mg/gummy	CBD.1
	3/9/2023		Potential CBD	0.378	%	CBD.1
	3/9/2023		Potential THC	< 0.010	%	CBD.1
	3/9/2023		Tetrahydrocannabivarin (THCV)	< 0.100	mg/gummy	CBD.1

Reported By:  Ryan Connelly, Chemistry Laboratory Manager, 3/10/2023

Methodology:

CBD.1 : Cannabinoids via MBL-HPLC2